@article {376,
	title = {Drug Review: Oteseconazole},
	journal = {International Journal of Pharmacology and Clinical Sciences},
	volume = {12},
	year = {2023},
	month = {February 2024},
	pages = {187-188},
	type = {Research Article},
	chapter = {187},
	abstract = {<p class="rtejustify">Registrations: It had been registered in the following countries: United Kingdom (U.K.), United States of America (USA), Canada, and Saudi Arabia (SA). Trade name (USA.); VIVJOA {\textregistered} Registration number (S.A.): Not available Insurance Drug Formulary (S.A.): Not available General Information: Registered Company: Mycovia Pharmaceuticals, Inc. Regulatory Status: R.X. Mechanism of Action: Inhibitor targeting the fungal sterol by inhibition of CYP51 results accumulation of 14-methylated sterols, which are toxic to fungi. <strong>Read more...</strong></p>
},
	doi = {10.5530/ijpcs.2023.12.25},
	author = {Juman Alsaab}
}
